Quality Assurance in Multi-Modality Oesophago-Gastric Cancer Clinical Trials: Past, Present and Future Perspectives

Area of Science:

• Clinical trial methodology
• Quality assurance in healthcare
• Oncology research

Background:

• Quality assurance (QA) is crucial for clinical trial integrity, ensuring accurate evaluation of treatments and patient safety.
• Significant variations in QA practices exist across different medical specialties within clinical trials.
• The complexity and diversity of modern clinical trials necessitate robust and standardized QA approaches.

Purpose of the Study:

• To examine the current state of quality assurance (QA) in clinical trials across various specialties.
• To highlight advancements in centralized QA processes, exemplified by the Radiotherapy Trials Quality Assurance (RTTQA) group in the UK.
• To identify ongoing challenges and potential negative effects associated with QA implementation in clinical research.

Main Methods:

• Review of current QA practices in radiotherapy, surgery, systemic anti-cancer therapy (SACT), pathology, and radiology.
• Case study analysis using examples from contemporary oesophago-gastric cancer trials.
• Exploration of international QA frameworks, such as those developed by the EORTC.

Main Results:

• The UK has centralized radiotherapy QA through the RTTQA group, enhancing consistency and efficiency.
• Standardized surgical QA is progressing but not yet universal; SACT QA faces challenges with under-reporting and diverse agents.
• QA in pathology and radiology is expanding due to increasing trial complexity; international QA implementation faces uncertainties.

Conclusions:

• Centralized and multidisciplinary QA approaches, like RTTQA, offer significant benefits for clinical trial quality.
• Addressing QA challenges in SACT, pathology, and radiology is essential for maintaining trial integrity.
• Recognizing and mitigating potential negative effects of QA is as important as acknowledging its benefits for successful clinical research.